January 10, 2017 / 11:57 AM / 3 years ago

Supreme Court will not hear patent dispute over Bayer contraceptives

The U.S. Supreme Court on Monday declined to hear Merck & Cie’s appeal of a lower court’s ruling invalidating its patent on a vitamin B compound used in Bayer AG birth control pills, clearing the way for the launch of generic versions of the contraceptives.

The justices left intact a ruling by the U.S. Court of Appeals for the Federal Circuit that the inventions described in the patent were commercially offered for sale more than a year before the patent application was filed, which is prohibited by the “on-sale bar” of the U.S. Patent Act.

To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2j3bdBq

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below